Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Sep 05
Show Filter
8:00am - 8:50am 50 mins
8:50am - 9:00am 10 mins
Chairperson's Opening Remarks
  • Kristina Bieker-Brady - Partner, McDermott Will & Emery
9:00am - 9:30am 30 mins
Comparing and Contrasting the Microbiome Revolution
  • Keith Batchelder, MD - CEO and Founder, Genomic Healthcare Strategies
  • Lynn Bry - Director, Massachusetts Host-Microbiome Center, Dept. Pathology, Brigham & Women's Hospital
  • Both trends are more than just new science and technology: new business models and stakeholder relationships are being produced
  • Several years history of the impact and changes created by Personalized Medicine, the Microbiome revolution is just beginning
  • What lessons can be learned from the Personalized Medicine Revolution that apply to the Microbiome
  • Insights might help pick winning strategies for Microbiome Therapeutics and Diagnostics companies
9:30am - 10:00am 30 mins
Emerging Microbial Therapeutics - Moving Beyond the Gut
  • Nikole Kimes, PhD - Founder & Chief Scientific Officer, Siolta Therapeutics

Siolta Therapeutics, an emerging biotech company in San Francisco, has developed a systems approach to live biotherapeutic product (LBP) development for the prevention and treatment of inflammatory diseases. Their proprietary platform provides 1) patient stratification, 2) immunomodulatory assessment, and 3) rationally engineered microbial therapeutics for targeted treatments. Siolta’s current focus is on the clinical development of its lead product to prevent and treat allergic asthma.

10:00am - 10:30am 30 mins
Standards for Microbiome Measurements
  • Scott Jackson - Leader – Complex Microbial Systems Group, Biosystems and Biomaterials Division, National Institute of Standards and Technology

Appreciation for the role of microbes in our lives has been growing rapidly, but the measurement science needed to understand and fully exploit microbial systems has developed at a much slower pace than the industries dependent on them demand. NIST is developing standards for microbiome measurements that will enable federal, academic, and industry labs to reliably reproduce and advance each other's results. Microbiome standards will support research investigations and commercial translation of microbiome science by providing measurement assurance tools: standardized protocols, reference materials, validated measurements and critically evaluated reference data

10:30am - 11:00am 30 mins
Morning Coffee and Networking
11:00am - 11:30am 30 mins
Incorporating NGS in the Development of Microbiome Therapeutics
  • Michalis Hadjithomas - Microbiome Lead Scientist, DNANexus

Next Generation Sequencing (NGS) has become an integral part of the therapeutic product development process. It is especially important in live bio-therapeutic product development, specifically for performing quality control, characterizing the safety of microbial strains, informing patient selection for clinical trials, monitoring changes in the microbiome, and enabling downstream discovery.

However, there are challenges associated with incorporating NGS data in the development of microbiome therapeutics:

  • Massive amount of data produced
  • Lack of established guidelines for the proper analysis of these data
  • Strict security and compliance requirements

In this presentation, we will discuss how a leading pharmaceutical company uses the DNAnexus Platform to address these issues. We will also present our work to crowdsource the improvement of NGS-based methods through community challenges on the Mosaic Microbiome Platform.

11:30am - 12:00pm 30 mins
Nutrition and the Gut Microbiome: Where Are We Now? Where Are We Going?
  • Leigh Frame - Program Director, Integrative Medicine, The George Washington School of Medicine and Health Sciences

When the gut microbiome (gBiome) is in an unhealthy state, an individual is in dysbiosis, which may be related to their diet and its nutritional value. The role of nutrition and the gBiome in health and disease has rapidly grown with the understanding of each, their interactions, and the links to gastrointestinal disease, obesity, and chronic disease. In the last decade, the availability of affordable next generation sequencing and gnotobiotics (germ-free animal models) has facilitated a major advancement in our understanding of the gBiome and the interaction with nutrition.

12:00pm - 12:30pm 30 mins
Novel antimicrobials and microbiome-based therapeutics
  • Akintunde Emiola, PhD - PostDoctoral associate, The Jackson Laboratory
12:30pm - 1:30pm 60 mins
Networking Lunch
1:30pm - 2:00pm 30 mins
Microbiome Inspired Therapeutics to Treat Neurological Diseases and Disorders
  • David Donabedian, PhD - CEO, Co-Founder, Axial Biotherapeutics

The relation between the gut microbiome and our neurological health has become very clear in recent years. Axial is developing new drug candidates to affect the microbiome and its metabolites, for potential treatments of neurological diseases, starting with Parkinson’s and autism spectrum disorder (ASD). We will discuss our ASD and Parkinson’s pipeline, as it approaches the clinic.

2:00pm - 2:30pm 30 mins
Mining the gut microbiome: a new source of targets and small molecules for treating chronic disorders
  • Rodolphe Clerval - CBO, Enterome

Gut microbiome plays a crucial role in the building-up of our immunity system at birth. It is a life-long personal and natural protection but increasing evidence suggests that dysregulated immune responses against commensal microbes in the gut are strongly involved in Inflammatory Bowel Diseases, Oncology, Metabolic disorders, Depression, Allergies amongst numerous diseases. 

Our target and drug discovery platform is based on full sequencing and mapping of total fecal bacterial gene content that leads to the characterization of the gut metagenome associated with a disease phenotype. This technology enables the identification of genes and pathways of interest associated with the development of diseases. 

The metagenomics dataset generated is then associated with a high throughput screening platform that allows the discovery of news drugs and targets. Two lead programs were discovered through this platform: EB8018 is an oral and non-systemic small molecule drug candidate that is designed to block FimH, a key virulence factor expressed by pro-inflammatory Enterobacteria. EB8018 prevents colonization of gut wall, mucosal inflammatory cytokine production and entry of such bacteria into the gut wall. E0510 : this program aims to discover novel bacterial-derived cancer antigens that are expressed in human gut microbiome. The first preclinical candidate (E02401) has demonstrated strong potency to induce T-cell activation against solid tumors. Enterome has entered clinical development stage, with EB8018 being currently evaluated in Crohn’s patients and E02401 will be tested in cancer patients

2:30pm - 2:45pm 15 mins
Chairperson Remarks
  • Kristina Bieker-Brady - Partner, McDermott Will & Emery
2:45pm - 3:30pm 45 mins
Keynote Speaker at Biotech Week Boston: High-Impact Ideas and Use-Inspired Research - A Chat with MIT's Bob Langer on How to Create Innovations That Matter
  • Robert Langer, ScD - David H. Koch Institute Professor, Massachusetts Institute of Technology

Robert Langer, the legendary MIT chemical engineer behind countless biotech startups, sits down with Amy Schulman, who is CEO of a company they co-founded called Lyndra. They will chat about how to turn ideas into innovations that make a difference.

3:30pm - 4:00pm 30 mins
Colloidal oatmeal for prebiotic skin care
  • Fang Liu-Walsh - Principal Scientist, Skin Biology and Biodelivery, Johnson & Johnson
4:00pm - 5:00pm 60 mins
Networking Reception
5:00pm - 7:00pm 120 mins
Grand Opening of the Poster & Exhibit Hall and Cocktail Reception

Connect with thousands of like-minded attendees, speakers, sponsors and exhibitors during the grand opening of our exhibit hall.  Enjoy a decadent display of hors d'oeuvres and grab a glass of wine/beer as our exhibitors showcase today's latest technologies in bioprocessing.